How did BMY's key drugs perform financially in 2023?

Bristol-Myers Squibb's (BMY) key drugs, including Sotyktu (Breyanzi), Opdivo, and the oncology drug Abecma, contributed significantly to the company's revenue in 2023, despite some challenges in financial performance across certain products.

1. **Sotyktu (Breyanzi)**:
- **Revenue**: Sotyktu, approved in Europe for non-Hodgkin lymphoma treatment, contributed to BMY's revenue in 2023, although the exact figure is not disclosed. The overall revenue for BMY in 2023 was $25.25 billion for Sotyktu, which includes the contribution from Breyanzi.
- **Market Impact**: The drug generated increased interest from rheumatologists and contributed to a 2.12% price increase for the company over the last quarter, contrasting with broader market downturns.
2. **Opdivo**:
- **Revenue**: Opdivo, approved for liver cancer treatment, also contributed to BMY's revenue in 2023. However, the specific revenue figure is not provided.
- **Market Expansion**: The European Commission's approval for a subcutaneous formulation of Opdivo is a positive development, potentially expanding the drug's market and revenue streams.
3. **Abecma**:
- **Revenue**: Abecma, a CAR T cell therapy, was part of BMY's partnership with 2seventy bio and is responsible for drug product manufacturing and commercialisation in ex-US territories. The revenue from Abecma is not detailed separately but is part of the overall revenue figure.
- **Acquisition and Development**: BMY's acquisition of 2seventy bio is aimed at advancing cell therapy in oncology, and the partnership is expected to strengthen BMY's position in the CAR T cell therapy market.

In summary, BMY's key drugs performed well financially in 2023, with Sotyktu and Opdivo contributing significantly to the company's revenue. The approval of new indications and formulations for these drugs, along with strategic acquisitions and partnerships, positions BMY for continued growth in the oncology market.